Price (delayed)
$13.33
Market cap
$561.38M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.22
Enterprise value
$438.82M
Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel,
There are no recent dividends present for URGN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.